Important notice regarding Inveltys

Posted in Latest News on August 7, 2019.

Important notice regarding Inveltys:

The board approved Inveltys (loteprednol etabonate ophthalmic suspension) 1% for addition to Rule 64B13-18.002. Effective August 5, 2019, Licensees are now permitted to prescribe Inveltys.



More Latest News

Fourth Quarter Performance Report
September 2, 2022

Released for the
2021 – 2022 Fiscal Year Continue reading


Website Server Maintenance Notice
July 5, 2022

Please be aware of website server maintenance for MQA Websites beginning Friday, July 8th at 5:00PM EST. Click here for more information. Continue reading